» Articles » PMID: 37752942

A Study of Genetic Heterogeneity in Autism Spectrum Disorders Based on Plasma Proteomic and Metabolomic Analysis: Multiomics Study of Autism Heterogeneity

Overview
Journal MedComm (2020)
Specialty Health Services
Date 2023 Sep 27
PMID 37752942
Authors
Affiliations
Soon will be listed here.
Abstract

Genetic heterogeneity poses a challenge to research and clinical translation of autism spectrum disorder (ASD). In this study, we conducted a plasma proteomic and metabolomic study of children with ASD with and without risk genes ( mutation) and controls to explore the impact of genetic heterogeneity on the search for biomarkers for ASD. In terms of the proteomic and metabolomic profiles, the groups of children with ASD carrying and those not carrying mutation tended to cluster and overlap, and integrating them yielded differentially expressed proteins and differential metabolites that effectively distinguished ASD from controls. The mechanisms associated with them focus on several common and previously reported mechanisms. Proteomics results highlight the role of complement, inflammation and immunity, and cell adhesion. The main pathways of metabolic perturbations include amino acid, vitamin, glycerophospholipid, tryptophan, and glutamates metabolic pathways and solute carriers-related pathways. Integrating the two omics analyses revealed that L-glutamic acid and malate dehydrogenase may play key roles in the pathogenesis of ASD. These results suggest that children with ASD may have important underlying common mechanisms. They are not only potential therapeutic targets for ASD but also important contributors to the study of biomarkers for the disease.

Citing Articles

Autism spectrum disorder: pathogenesis, biomarker, and intervention therapy.

Zhuang H, Liang Z, Ma G, Qureshi A, Ran X, Feng C MedComm (2020). 2024; 5(3):e497.

PMID: 38434761 PMC: 10908366. DOI: 10.1002/mco2.497.


Metabolomic analysis of plasma biomarkers in children with autism spectrum disorders.

Liu J, Tan Y, Zhang F, Wang Y, Chen S, Zhang N MedComm (2020). 2024; 5(3):e488.

PMID: 38420161 PMC: 10901282. DOI: 10.1002/mco2.488.


A study of genetic heterogeneity in autism spectrum disorders based on plasma proteomic and metabolomic analysis: multiomics study of autism heterogeneity.

Tang X, Feng C, Zhao Y, Zhang H, Gao Y, Cao X MedComm (2020). 2023; 4(5):e380.

PMID: 37752942 PMC: 10518435. DOI: 10.1002/mco2.380.

References
1.
Ormstad H, Bryn V, Verkerk R, Skjeldal O, Halvorsen B, Saugstad O . Serum Tryptophan, Tryptophan Catabolites and Brain-derived Neurotrophic Factor in Subgroups of Youngsters with Autism Spectrum Disorders. CNS Neurol Disord Drug Targets. 2018; 17(8):626-639. DOI: 10.2174/1871527317666180720163221. View

2.
El-Fishawy P, State M . The genetics of autism: key issues, recent findings, and clinical implications. Psychiatr Clin North Am. 2010; 33(1):83-105. PMC: 2841771. DOI: 10.1016/j.psc.2009.12.002. View

3.
Tarlungeanu D, Deliu E, Dotter C, Kara M, Janiesch P, Scalise M . Impaired Amino Acid Transport at the Blood Brain Barrier Is a Cause of Autism Spectrum Disorder. Cell. 2016; 167(6):1481-1494.e18. PMC: 5554935. DOI: 10.1016/j.cell.2016.11.013. View

4.
Cui Y, Xu B, Zhang X, He Y, Shao Y, Ding M . Diagnostic and therapeutic profiles of serum bile acids in women with intrahepatic cholestasis of pregnancy-a pseudo-targeted metabolomics study. Clin Chim Acta. 2018; 483:135-141. DOI: 10.1016/j.cca.2018.04.035. View

5.
Iakoucheva L, Muotri A, Sebat J . Getting to the Cores of Autism. Cell. 2019; 178(6):1287-1298. PMC: 7039308. DOI: 10.1016/j.cell.2019.07.037. View